A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Trial Profile

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Exemestane (Primary) ; Anastrozole; Celecoxib
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 31 Mar 2017 Results (n=14729) assessing impact of baseline BMI and weight change on clinical outcomes with adjuvant breast cancer systemic therapy using data from six trials (chemotherapy trials-MA.5-NCI-V90-002 and MA.21-NCT00014222, endocrine therapy trials-MA.12-NCT00002542 and MA.14-NCT00002864, MA-27-NCT00066573 and trastuzumab trial-HERA, NCT00045032), published in the Annals of Oncology.
    • 06 Oct 2009 Last checked against Oregon Health and Science University Cancer Institute
    • 29 Aug 2009 Additional lead trial centres identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top